Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET

Company Participants

Allison Wey - Senior Vice President, Investor Relations and Corporate Communications

Paul Edick - Chairman and CEO

Steve Pieper - Chief Financial Officer

Conference Call Participants

Glen Santangelo - Jefferies

David Amsellem - Piper Sandler

Oren Livnat - H.C. Wainwright

Roanna Ruiz - SVB Securities

Operator

Good evening or good afternoon. And welcome to the Xeris Biopharma Third Quarter 2022 Financial Results Call. My name is Adam, and I will be your operator today. [Operator Instructions]

I will now hand the floor over to Allison Wey, Senior Vice President of Investor Relations and Corporate Communications to begin. So, Allison, please go ahead when you are ready.

Allison Wey

Thank you, Adam. Good morning. And welcome to Xeris Biopharma’s third quarter 2020 financial results and corporate update conference call and webcast. A press release with the company’s third quarter 2022 financial results was issued earlier this morning and can be found on our website.

We are joined this morning by Paul Edick, Chairman and CEO; and Steve Pieper, our CFO. Paul will provide opening remarks, Steve will provide details on our financial results and after a few closing remarks by Paul, we will open up the call for Q&A.

Before we begin, I would like to remind you that this call will contain forward-looking statements concerning Xeris’ business practices, Xeris’ future expectations, plans, prospects, clinical approvals, commercialization, corporate strategy, performance and the impact of COVID-19 on Xeris’ business practices, which constitute forward-looking statements for the purposes of the Safe Harbor provision under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements, as a result of various important factors, including the effect of uncertainties related to the COVID-19 pandemic on the U.S. and global markets, Xeris’ business, financial condition, operations, clinical trials and third-party suppliers and manufacturers, and other risk factors including those discussed in our filings with the SEC.

In addition, any forward-looking statements represent our views only as of the date of this call and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligations to update such statements.

I will now turn the call over to Paul.

Paul Edick

Thanks, Allison. Good morning to everyone and thank you for joining us today. Before getting into the results of the quarter, I want to reiterate a few things we talked about on our second quarter call regarding what we are trying to build at Xeris.